Our History

Myrobalan Co-founder, Professor Zhigang He, Published original research in Neuron (2020), highlighting the importance of CSF1R and GPR17 and Remyelination.

Scientific co-founders Professors Zhigang He and Professor Guoping Feng decided to focus on novel mechanisms promoting remyelination and anti-neuroinflammation, identifying key targets that play critical roles in these processes.

Myrobalan Therapeutics was incorporated. Co-founder Dr. Jing Wang appointed as CEO.

Myrobalan Therapeutics raised $10M in seed funding.

Myrobalan's first research lab opened at the Cambridge Scientific Incubator in Watertown, MA.

A second research site launched in Nanjing, China, under Myrobalan's wholly owned subsidiary.

Myrobalan graduated from the Cambridge Scientific Incubator and began R&D operations in Medford, MA.

Myrobalan selected to join J-Labs Shanghai.

Myrobalan appointed a robust team of Board of Directors Advisors and recruited a team of experience scientific advisors.

The company nominated a preclinical candidate for the CSF1R program.

Myrobalan raised $24M in Series A (First Closing).

Received ALS Association Grant for CSF1R.

Raised an additional $9M in financing, Grant Bogle named to Myrobalan's Board of Directors.